
Sanofi, AstraZeneca and Sobi simplify contractual agreements
Sanofi, AstraZeneca and Sobi simplify contractual agreements Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with…




